FHL 701
Alternative Names: FHL-701Latest Information Update: 28 Aug 2023
At a glance
- Originator Forest Hills Lab
- Class Antidementias; Antiparkinsonians; Monoclonal antibodies
- Mechanism of Action Interleukin 12 subunit p40 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alzheimer's disease; Parkinson's disease
Highest Development Phases
- Preclinical Alzheimer's disease; Parkinson's disease
Most Recent Events
- 24 Jul 2023 FHL 701 is available for licensing as of 24 Jul 2023. https://foresthillslab.com/#about
- 20 Jul 2023 Preclinical trials in Alzheimer's disease in China (Parenteral) before July 2023 (Forest Hills Lab website, July 2023)
- 20 Jul 2023 Preclinical trials in Parkinson's disease in China (Parenteral) before July 2023 (Forest Hills Lab website, July 2023)